TAK - Codexis expands collaboration with Takeda in rare genetic disorder

Codexis (CDXS) has expanded its strategic collaboration and license agreement with Takeda Pharmaceutical (TAK) for the research and development of an additional gene therapy for a lysosomal storage disorder.This brings the total number of programs under the agreement to four. Under the terms of the original agreement inked in March 2020, the parties began collaborative work on three initial programs. Takeda had the contractual option to expand the collaboration into a fourth program.Codexis is responsible for the creation of novel enzyme sequences for advancement of gene therapies.Takeda is responsible for the pre-clinical and clinical development of gene therapy products resulting from the collaboration programs.

For further details see:

Codexis expands collaboration with Takeda in rare genetic disorder